NASDAQ INMB
SIGN UP
Search
What’s New
About
Back
Corporate Overview
Management
Directors
Therapies
Back
Pipeline
INKmune™ – Cancer
Back
Overview
Clinical trials
Publications
Videos
INB03 – Cancer
Back
Overview
Presentations
Publications
Videos
XPro1595 – Alzheimer's
Back
Overview
Clinical trials
Publications
Videos
Posters
XPRO1595 – TRD
Back
Overview
Videos
Investors
Back
Corporate Governance
Presentation
Filings
Stock Quote
Analyst Coverage
News and Media
Back
2023
2022
2021
2020
2019
2018
2017
Contact
Back
Contact Us
Subscribe for Updates
2023
2022
2021
2020
2019
2018
2017
2017
Title Filter
All
Corporate
General
Title
Date
INmune Bio Appoints Edgardo Baracchini to its Board of Directors, Gains Additional Licensing and Business Development Expertise
16 Oct, 2017
INmune Bio to Present at the BIO Investor 2017 Healthcare Conference
11 Oct, 2017
INmune Bio Licenses INB03, a First-in Class Innate Immune System Check-Point Inhibitor that Targets Myeloid Derived Suppressor Cells in Cancer
10 Oct, 2017
INmune Bio Licenses Technology to Deplete Myeloid Derived Suppressor Cells of the Innate Immune System in Patients with Cancer
09 Oct, 2017
INmune Bio Adds Clinical Development and Product Development Expertise with the Appointment of Tim Schroeder to its Board of Directors
26 Sep, 2017
INmune Bio Co-Founder, Professor Mark Lowdell, Named One of Europe’s Academic-Entrepreneur Superstars
01 Mar, 2017
Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm EST